← Back to Search

Darolutamide + ADT for Prostate Cancer (ARANOTE Trial)

Phase 3
Waitlist Available
Research Sponsored by Bayer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2
Histologically or cytologically confirmed adenocarcinoma of prostate
Must not have
Treatment with radiotherapy within 2 weeks before randomization
Inability to swallow oral medications
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 55 months
Awards & highlights
Pivotal Trial

Summary

This trial is testing a drug called darolutamide combined with a common hormone-lowering therapy in patients whose prostate cancer has spread but still responds to hormones. The goal is to see if this combination can effectively and safely slow down the cancer's growth. Darolutamide was approved in 2019 for a specific type of prostate cancer.

Who is the study for?
Men with confirmed metastatic hormone-sensitive prostate cancer, who have started ADT within the last 12 weeks and are in good physical condition (ECOG PS of 0-2) can join. They must not have had certain heart conditions or other cancer treatments like chemotherapy for prostate cancer in the past 6 months.
What is being tested?
The trial is testing if adding Darolutamide to standard ADT improves outcomes for men with metastatic hormone-sensitive prostate cancer compared to ADT alone. Participants will either receive Darolutamide or a placebo alongside their regular ADT treatment.
What are the potential side effects?
Darolutamide may cause fatigue, pain, blood disorders, liver enzyme changes, rash, and fractures. Side effects vary by individual and should be discussed with a healthcare provider.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am able to care for myself and perform daily activities.
Select...
My prostate cancer was confirmed by a lab test.
Select...
My cancer has spread to other parts of my body.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not had radiotherapy in the last 2 weeks.
Select...
I cannot swallow pills.
Select...
I have not used specific hormone therapies, chemotherapy, or other treatments for prostate cancer recently.
Select...
I haven't had a stroke, heart attack, severe heart issues, or heart surgery in the last 6 months.
Select...
My blood pressure is high (over 160/100) despite taking medication.
Select...
I have a GI condition or had surgery that may affect how I absorb medication.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 55 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 55 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Radiological progression-free survival (rPFS)
Secondary study objectives
Overall survival (OS)
PSA undetectable rates (<0.2 ng/mL)
Time to PSA progression
+3 more

Side effects data

From 2022 Phase 3 trial • 1209 Patients • NCT01715285
38%
Hypertension
24%
Hypokalaemia
20%
Back Pain
17%
Alanine Aminotransferase Increased
16%
Arthralgia
15%
Aspartate Aminotransferase Increased
15%
Hot Flush
14%
Fatigue
14%
Hyperglycaemia
14%
Bone Pain
12%
Pain in Extremity
11%
Constipation
10%
Oedema Peripheral
10%
Anaemia
9%
Weight Increased
8%
Nasopharyngitis
8%
Headache
7%
Influenza
7%
Upper Respiratory Tract Infection
7%
Urinary Tract Infection
7%
Nausea
7%
Vomiting
7%
Blood Lactate Dehydrogenase Increased
7%
Cough
6%
Diarrhoea
5%
Asthenia
5%
Musculoskeletal Pain
5%
Insomnia
4%
Abdominal Pain
4%
Decreased Appetite
2%
Pneumonia
2%
Spinal Cord Compression
2%
Urinary Retention
1%
Angina Pectoris
1%
Myocardial Infarction
1%
Bronchitis
1%
Acute Coronary Syndrome
1%
Cardiac Failure
1%
Pyrexia
1%
Bronchopneumonia
1%
Haematuria
1%
Renal Failure
1%
Urinary Tract Obstruction
1%
Deep Vein Thrombosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo + ADT
DB Period Placebo to Open-label Extension (OLE) Abiraterone Acetate
Abiraterone Acetate+Prednisone+ADT

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Darolutamide+ADTExperimental Treatment2 Interventions
Participants will receive darolutamide 600 mg (2 tablets of 300 mg) twice daily with food and ADT of investigator's choice as standard therapy
Group II: Placebo+ADTPlacebo Group2 Interventions
Participants will receive placebo twice daily with food and ADT of investigator's choice as standard therapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Darolutamide (Nubeqa, BAY1841788)
2024
Completed Phase 3
~4180

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Prostate cancer treatments often target the androgen receptor pathway, which is critical for the growth and survival of prostate cancer cells. Androgen deprivation therapy (ADT) reduces the levels of androgens (male hormones) in the body, thereby limiting the stimulation of prostate cancer cells. Androgen receptor inhibitors, such as darolutamide, block the androgen receptors on cancer cells, preventing androgens from binding and activating these cells. This dual approach is effective in slowing disease progression and improving survival rates. Understanding these mechanisms helps patients appreciate the rationale behind their treatment plans and the importance of adhering to them.

Find a Location

Who is running the clinical trial?

BayerLead Sponsor
2,270 Previous Clinical Trials
25,508,063 Total Patients Enrolled
45 Trials studying Prostate Cancer
26,961 Patients Enrolled for Prostate Cancer
Orion Corporation, Orion PharmaIndustry Sponsor
138 Previous Clinical Trials
44,270 Total Patients Enrolled
5 Trials studying Prostate Cancer
407 Patients Enrolled for Prostate Cancer

Media Library

Androgen Deprivation Therapy (ADT) Clinical Trial Eligibility Overview. Trial Name: NCT04736199 — Phase 3
Prostate Cancer Clinical Trial 2023: Androgen Deprivation Therapy (ADT) Highlights & Side Effects. Trial Name: NCT04736199 — Phase 3
Androgen Deprivation Therapy (ADT) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04736199 — Phase 3
Prostate Cancer Research Study Groups: Darolutamide+ADT, Placebo+ADT
~143 spots leftby Oct 2025